FDA Recall

Regulatory Event

On August 5, 2026, Zydus Pharmaceuticals (USA) Inc. initiated a recall of one lot of Mirabegron Extended-Release Tablets, 25 mg, 30-count bottles — lot E408618, NDC 70710-1159-3, expiration November 30, 2026 — manufactured by Zydus Lifesciences Ltd. in Matoda, Ahmedabad, India, and distributed nationwide. FDA has since officially classified this as a Class II recall. The reason cited is the presence of a nitrosamine impurity above the FDA-recommended acceptable intake limit — a finding entirely distinct from the drug’s identity, potency, or sterility, and one that reflects a specific, well-characterized manufacturing control category rather than an isolated quality lapse.

A Class II classification here should not be read as low-stakes housekeeping. FDA’s own public guidance is direct on the actual magnitude of individual risk: a patient taking a drug containing nitrosamines at or below the acceptable daily intake limit every day for 70 years is not expected to have an increased cancer risk, and the agency explicitly advises patients not to stop a prescribed medication over a nitrosamine recall. What the recall actually signals is not an acute patient hazard but a manufacturing process control gap — a specification exceedance discovered after release, meaning the control strategy in place for this product did not detect or prevent an impurity above the qualified limit before the lot reached distribution. That gap is the proper subject of analysis here, not the individual-patient cancer-risk framing that dominates consumer coverage of nitrosamine recalls.

What the Record Documents

Nitrosamine impurities in oral solid dosage products typically form through one of a small number of well-documented pathways: a secondary or tertiary amine present in the active pharmaceutical ingredient (API), an excipient, or a degradant reacting with a nitrosating agent — commonly a nitrite impurity in an excipient, or nitrogen oxides introduced during a manufacturing or packaging step — under conditions of heat, acid, or catalytic influence during synthesis, formulation, or storage. For an extended-release tablet specifically, the polymer and excipient system used to control drug release often introduces additional amine-bearing or nitrite-contributing materials beyond what a simple immediate-release formulation would use, which is one reason nitrosamine risk assessments must be conducted at the specific formulation level rather than assumed to transfer from an immediate-release version of the same molecule.

FDA’s guidance on Control of Nitrosamine Impurities in Human Drugs establishes an expectation that sponsors conduct a documented risk assessment covering the synthetic route, formulation, and packaging of each product, identify potential nitrosamine-forming pathways specific to that product, and implement control strategies — including specification limits and analytical testing where risk is identified — proportionate to that assessment. That expectation extends to periodic reassessment, not a one-time filing exercise, because manufacturing processes and supply chains are not static over a product’s commercial life. 21 CFR 211.165(a) requires that each batch be tested to ensure it meets established specifications before release, and where a nitrosamine specification has been established for a product following a risk assessment, batch release testing against that specification is the control point that should catch an exceedance before distribution. A nitrosamine finding discovered post-release, as occurred here, indicates either that the risk assessment did not anticipate this specific impurity or pathway for this formulation, or that release testing for a known nitrosamine risk was not sufficiently sensitive or was not performed on this lot as the control strategy intended.

Technical and Quality Context

Nitrosamine impurities have driven a sustained, multi-year wave of recalls across therapeutic classes since 2018, beginning with valsartan and extending through ranitidine, metformin, and numerous other oral solid dosage products, largely because early risk assessments across the generics industry did not anticipate nitrosamine-forming pathways introduced by specific manufacturing processes, catalysts, or excipient sources that were not part of originator-product development data. The pattern across these events is consistent: a nitrosamine risk assessment scoped too narrowly — to the API alone, or to a different formulation of the same molecule — misses a pathway specific to the actual commercial process, and that gap surfaces only through post-release or periodic surveillance testing rather than routine batch release. Notably, this same underlying impurity class connects back to valsartan, the molecule at the center of the industry’s original 2018 nitrosamine reckoning — a reminder that nitrosamine control is not a problem any single therapeutic class has solved and closed out, but an ongoing control-strategy discipline that applies across API sources, formulation types, and manufacturing processes as each is introduced or changed. A risk assessment that was adequate at initial approval does not remain adequate indefinitely; it requires re-evaluation whenever a synthetic route, excipient source, or manufacturing process changes, since any of those changes can introduce a nitrosamine-forming pathway that was not present, and therefore not tested for, in the original assessment.

Manufacturers of oral solid dosage products, particularly extended-release and other complex formulations with more extensive excipient systems than immediate-release equivalents, should treat this event as a prompt to verify three things in their own control strategies. First, whether nitrosamine risk assessments have been conducted at the specific formulation and process level actually used in commercial manufacturing, rather than extrapolated from a related but distinct formulation or from originator-product data. Second, whether analytical methods used for nitrosamine testing are validated with sufficient sensitivity for the specific nitrosamine species most likely to form given the product’s synthetic route and excipient system. Third, whether nitrosamine testing is incorporated into routine batch release specifications for products where a credible formation pathway has been identified, rather than treated as a one-time qualification study.

Decision Relevance

This is precisely the kind of gap XGene Consulting works with generic and branded manufacturers to close — formulation-specific nitrosamine risk assessment, analytical method validation for trace-level nitrosamine detection, and control strategy design that incorporates nitrosamine specifications into routine batch release rather than periodic surveillance alone. If your product’s nitrosamine risk assessment was last updated for a different formulation or an earlier manufacturing process than the one currently in commercial use, that is worth a conversation now, not after the next recall notice.